Jyong Biotech Ltd
MENS37.857USD
-0.883-2.28%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.88BMarktkapitalisierung
--KGV TTM
mehr Informationen über Jyong Biotech Ltd Unternehmen
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Jyong Biotech Ltd Informationen
BörsenkürzelMENS
Name des UnternehmensJyong Biotech Ltd
IPO-datumJun 17, 2025
CEOMr. Fu Feng Kuo
Anzahl der mitarbeiter29
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse23F-3, No.95, Section 1, Xintai 5th, Xizhi District
StadtNEW TAIPEI
BörseNASDAQ Global Market Consolidated
LandTaiwan
Postleitzahl221
Telefon886227325205
Websitehttps://jyongbio.com/
BörsenkürzelMENS
IPO-datumJun 17, 2025
CEOMr. Fu Feng Kuo
Führungskräfte von Jyong Biotech Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
--
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Dr. Wanwen (Angela) Su
Dr. Wanwen (Angela) Su
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Mr. Ming Tsan Hsu
Mr. Ming Tsan Hsu
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
--
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Dr. Wanwen (Angela) Su
Dr. Wanwen (Angela) Su
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Oct 27
Aktualisiert: Mon, Oct 27
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Andere
37.80%
Aktionäre
Aktionäre
Anteil
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Andere
37.80%
Aktionärstypen
Aktionäre
Anteil
Corporation
62.20%
Hedge Fund
0.09%
Investment Advisor/Hedge Fund
0.07%
Investment Advisor
0.03%
Andere
37.61%
Institutionelle Beteiligung
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
5
148.54K
0.20%
+138.11K
2025Q2
7
47.29M
62.20%
+47.29M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Perfect Minds Co Ltd
25.35M
33.34%
+25.35M
--
Jun 17, 2025
Laxton Investments Company Ltd
7.63M
10.04%
+7.63M
--
Jun 17, 2025
Linkage Gladden Enterprise Ltd
6.86M
9.03%
+6.86M
--
Jun 17, 2025
Peak Valley International Co., Ltd.
5.10M
6.71%
+5.10M
--
Jun 17, 2025
Honest Dynasty Ltd
2.34M
3.08%
+2.34M
--
Jun 17, 2025
Citadel Advisors LLC
70.97K
0.09%
+70.97K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
10.43K
0.01%
--
--
Aug 31, 2025
HRT Financial LP
22.92K
0.03%
+22.92K
--
Jun 30, 2025
Ying (Alfred)
4.00K
0.01%
+4.00K
--
Jun 17, 2025
Hsu (Fenglin)
3.00K
0%
+3.00K
--
Jun 17, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Fidelity Nasdaq Composite Index ETF
0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
